Navigation Links
Kosan Biosciences to Host Research & Development Day on October 31, 2007
Date:10/25/2007

on the "Events Calendar" tab under the same heading, "Investors/Press." A replay of the presentation will be available for 30 days following event. Please connect to Kosan's website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a registration program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical

trials in hematological cancers and in HER2-positive metastatic breast cancer.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 safety trial, with plans to pursue development in gastroesophageal reflux disease (GERD).

For additional information on Kosan Biosciences, please visit the company's website at ht
'/>"/>

SOURCE Kosan Biosciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)...  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), ... medical needs in the areas of inflammation, oncology and ... data from three of its biodefense programs at the ... on May 12-14, 2015 to be held at the ... St. Louis MO 63101. ...
(Date:5/4/2015)... , May 4, 2015   Tocagen Inc. ... interim data from Tocagen,s ongoing investigational studies were ... of the American Association of Neurological Surgeons (AANS)/Congress ... May 1-2, 2015, in Washington, D.C. ... held a meeting with FDA and continues to ...
(Date:5/4/2015)... 2015 Marianjoy Rehabilitation Hospital ... arm and hand impairments by acquiring the Armeo®Spring ... Terrace network site. , Secured through grant support ... highly-regarded treatment option for patients with upper extremity ... becomes one of just four Illinois providers offering ...
(Date:5/1/2015)... May 1, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... announced that it has priced an underwritten registered offering ... price of $9.00 per share, and granted the underwriters ... to an additional 585,000 shares of its common stock. ... million.  The offering is expected to close on May 6, ...
Breaking Biology Technology:Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 2Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 3Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 4Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 5Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 6Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 7Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 8Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 9Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 10Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 11Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 12Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5Marianjoy Acquires Armeo®Spring Arm and Hand Rehabilitation Exoskeleton at Oakbrook Terrace Facility 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3
... Calif., March 31 Sigma-Aldrich (Nasdaq: ... high quality services and oligonucleotides to Gene Oracle, an ... the agreement, Sigma-Aldrich will be the exclusive supplier of ... will engage in co-marketing efforts to promote the GeneIOS ...
... Endo Pharmaceuticals (Nasdaq: ENDP ) announced ... the company,s board of directors. Dr. Hutson retired ... in various research and leadership positions with that company, ... Research and Development and director of Pfizer,s pharmaceutical R&D ...
... MYL ) today announced that Matrix Laboratories ... 71.2% controlling interest, has received the first tentative approval ... the President,s Emergency Plan for AIDS Relief (PEPFAR) for ... Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg.Mylan Vice Chairman ...
Cached Biology Technology:Sigma-Aldrich Enters Exclusive Supply Agreement With Gene Oracle to Leverage Its Unique GeneIOS Gene Synthesis Platform 2Sigma-Aldrich Enters Exclusive Supply Agreement With Gene Oracle to Leverage Its Unique GeneIOS Gene Synthesis Platform 3Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors 2Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors 3Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors 4Mylan's Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R) 2
(Date:4/6/2015)... OXFORD, Conn. , Apr. 6, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... it has filed provisional patent 62/143028 for ... CLOSE-PROXIMITY COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces ... wireless payments. This patent surrounds the use of ...
(Date:4/2/2015)... 2015 According to preliminary estimates ... somewhat higher than 125 MSEK. This exceeds the guidance ... that revenues for Q1 2015 would be in line ... Q4 2014. The operating result for the first quarter ... interim report will as previously communicated be published on ...
(Date:4/1/2015)... April 1, 2015   Medisafe ™, the leading ... across iOS and Android smartphones ... biofeedback into the platform to allow patients to track ... the first time, patients will be able to visualize ... impacts important biometrics, such as glucose levels and blood ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... German . To further enhance ... Forschungsgemeinschaft (DFG, German Research Foundation) has established twelve new ... DFG,s relevant Grants Committee in Bonn. The new Research ... training at a highly specialised level within a structured ...
... can incite the body to attack its own nerve ... both viral and nerve proteins. The dual-receptor observation suggests ... be triggered in susceptible young adults afflicted with multiple ... Immunology scientists Qingyong "John" Ji, Antoine Perchellet, and Joan ...
... University of Illinois at Chicago have discovered that an ... down and inhibiting the formation of excess scar tissue ... this week in Nature Cell Biology . ... "recruited" to the wound site that rapidly produce extracellular ...
Cached Biology News:DFG establishes 12 new research training groups 2DFG establishes 12 new research training groups 3DFG establishes 12 new research training groups 4DFG establishes 12 new research training groups 5DFG establishes 12 new research training groups 6Virus infection may trigger unusual immune cells to attack nerves in multiple sclerosis 2Virus infection may trigger unusual immune cells to attack nerves in multiple sclerosis 3Virus infection may trigger unusual immune cells to attack nerves in multiple sclerosis 4Researchers discover mechanism that limits scar formation 2
... offer you a full range of ... advanced design parameters, effective synthetic siRNA ... you obtain quality results from your ... utilizes their proprietary B-Algo algorithm to ...
... The top-of-the-line PowerPac 3000 power supply ... available, ideal for isoelectric focusing, DNA ... gel electrophoresis, western blotting, and submerged ... W of powre, the PowerPac 3000 ...
... 3000 system, 220-240 V, is used for nucleic ... vertical slab gel format. The system includes the ... of separating nucleic acids with single base-pair resolution ... (IPC and bonded inner glass plate, outer glass ...
The optional fixed lens, 105 mm, is for use with the VersaDoc imaging systems for imaging small samples at high resolution....
Biology Products: